Biogen Inc stock page - price, fundamentals, dividends - iOCharts

BIIB

298.49
-1.70 (-0.57%)
Biogen Inc (NASDAQ, USD)
Healthcare >
Drug Manufacturers-General
Market cap
44.94B
Ent value
56.91B
Price/Sales
3.34
Price/Book
4.21
Div yield
-
Div growth
-
Growth years
-
FCF payout
1.93%
Trailing P/E
11.23
Forward P/E
14.36
PEG
12.48
EPS growth
20.50%
1 year return
8.75%
3 year return
-3.95%
5 year return
-0.40%
10 year return
11.80%
Last updated: 2021-09-20

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open297.94
Daily high301.58
Daily low296.31
Daily Volume854K
All-time high475.98
1y analyst estimate376.43
Beta0.42
EPS (TTM)26.25
Dividend per share-
Ex-div date-
Next earnings date20 Oct 2021

Downside potential

Loading...
Downside potential data
BIIBS&P500
Current price drop from All-time high-37.29%-4.23%
Highest price drop-90.00%-56.47%
Date of highest drop30 Dec 19949 Mar 2009
Avg drop from high-33.68%-11.47%
Avg time to new high34 days12 days
Max time to new high1711 days1805 days

DIVIDENDS

BIIB does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E11.23
Price to OCF10.62
Price to FCF12.22
Price to EBITDA8.16
EV to EBITDA10.34

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.34
Price to Book4.21
EV to Sales4.23

FINANCIALS

Per share

Loading...
Per share data
Current share count150.56M
EPS (TTM)26.25
FCF per share (TTM)24.13

Income statement

Loading...
Income statement data
Revenue (TTM)13.44B
Gross profit (TTM)11.64B
Operating income (TTM)4.45B
Net income (TTM)4.00B
EPS (TTM)26.25
EPS (1y forward)20.79

Margins

Loading...
Margins data
Gross margin (TTM)86.57%
Operating margin (TTM)33.07%
Profit margin (TTM)29.76%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.22B
Net receivables2.22B
Total current assets6.72B
Goodwill5.76B
Intangible assets2.99B
Property, plant and equipment3.85B
Total assets23.85B
Accounts payable573.50M
Short/Current long term debt7.65B
Total current liabilities3.17B
Total liabilities13.19B
Shareholder's equity10.66B
Net tangible assets1.93B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)4.23B
Capital expenditures (TTM)551.80M
Free cash flow (TTM)3.68B
Dividends paid (TTM)71.00M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity37.44%
Return on Assets16.25%
Return on Invested Capital22.09%
Cash Return on Invested Capital20.31%
COMPANY DETAILS
BIIB (Biogen Inc) company logo
Marketcap
44.94B
Marketcap category
Large-cap
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; and Capsigen Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Employees
9100
Investor relations
SEC filings
CEO
Josephine Price
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 21, 2021
Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.
September 21, 2021
In this article, we discuss the 10 hedge funds that are betting against Cathie Wood’s ARK Innovation ETF. If you want to skip our detailed analysis of these hedge funds, go directly to 5 Hedge Funds B...
September 21, 2021
33 early and late-stage clinical programs across modalities and innovative discovery platformsUniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading pi...
September 20, 2021
In the latest trading session, Biogen Inc. (BIIB) closed at $298.49, marking a -0.57% move from the previous day.
September 20, 2021
The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.
September 20, 2021
It wasn't long before fears about stocks in September came true. It's already proving to be a difficult month, especially for the S&P 500.
September 20, 2021
BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biog...
September 17, 2021
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.
September 17, 2021
VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profileData from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low d...
September 16, 2021
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN). SFN is a disorder in which only the small sensory cutan...
Next page